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INTRODUCTION
Cervical cancer is still associated with high mortality rates among
women worldwide (1). Tumor neovascularization plays a crucial
role in the development of solid tumors including cervical cancers.
Vascular endothelial growth factor (VEGF) is a potent mitogen
responsible for the induction of angiogenesis (2). VEGF mRNA
expression and microvessel density are significantly increased in
invasive carcinomas and high-grade intraepithelial lesions com-
pared with low-grade intraepithelial and benign squamous epithe-
lium lesions (3). High microvessel density is also significantly
associated with increased VEGF mRNA expression.
In cases of advanced stage cervical cancer, there are no signifi-
cant correlations between VEGF mRNA expression and prognos-
tic factors including histological type and lymph node metastasis,
although a significant relationship between VEGF mRNA expres-
sion and microvessel density was observed (4). Furthermore, no
significant correlation could be demonstrated between VEGF ex-
pression and clinicopathological parameters in cases of cervical
cancer (5). However, several studies have demonstrated that in-
creased microvessel density and VEGF expression are significantly
correlated with poorer prognosis in cases of cervical cancer (6-9).
Bevacizumab, an antibody targeting VEGF, exhibits antitumor
properties by inhibiting angiogenesis. Currently, it is used as an
effective drug in the treatment of lung, colorectal, and ovarian can-
cers. Recent research has focused on the effect of bevacizumab
against cervical cancer. In the GOG 240 trial, bevacitumab signifi-
cantly improved the overall survival when added to chemotherapy
for patients with persistent, recurrent, or metastatic cervical cancer
(10). Moreover, the U.S. Food and Drug Administration (FDA) has
approved bevacizumab for use in the patients with aggressive and
late-stage cervical cancer (11). Although VEGF can be a target in
the treatment of cervical cancer, it is unclear in which cases bevaci-
zumab will be the most effective. Therefore, we investigated poten-
tial correlations among VEGF expression, microvessel density, and
clinicopathological features in this study to determine whether
VEGF expression and microvessel density in invasive cervical can-
cer lesions are predictive of prognosis.
MATERIALS AND METHODS
Clinical materials
Fifty samples of invasive uterine cervical cancer tissues were ob-
tained from 26-70-years-old patients who provided informed con-
sent. The patients underwent surgical treatment at the Tokushima
University Hospital between 1998 and 2002. Tissue sections were
fixed in paraformaldehyde and embedded in paraffin for histopa-
thological examination and immunohistochemical staining. All cases
were staged according to the 1994 International Federation of Gy-
necology and Obstetrics criteria as follows : two patients were stage
Ia, 30 were stage Ib, five were stage IIa, and 13 were stage IIb.
Tumors were classified histologically on the basis of the World
Health Organization criteria as follows : 32 squamous cell carcino-
mas, 17 adenocarcinomas, and one adenosquamous carcinoma.
Immunohistochemistry
Tissue sections of 4-μm thickness were cut, dried overnight at
ORIGINAL
Clinical Significance of Vascular Endothelial Growth Factor
Expression and Microvessel Density in Invasive Cervical
Cancer
Yasuyo Saijo1, Hiroyuki Furumoto1,2, Kanako Yoshida1, Masato Nishimura1, and Minoru Irahara1
1Department of Obstetrics and Gynecology, Institute of Health Biosciences, the University of Tokushima Graduate School ; 2Department of Ob-
stetrics and Gynecology, Tokushima Red Cross Hospital, Tokushima, Japan
Abstract : To determine whether vascular endothelial growth factor (VEGF) expression and microvessel density
are predictive of prognosis in cases of invasive cervical cancer, correlations among VEGF expression, microves-
sel density, and clinicopathological parameters were identified. VEGF expression was evaluated in 50 cervical
cancer samples by immunohistochemical staining. Microvessel density was assessed by immunostaining for
CD31-positive endothelial cells in the most vascularized areas of tumors. VEGF expression and microvessel
density were significantly higher in adenocarcinomas than in squamous cell carcinomas. However, in cases of
adenocarcinoma, no significant correlations were found among VEGF expression, microvessel density, and
clinicopathological parameters. In contrast, for squamous cell carcinomas, microvessel density was significantly
higher in cases at an advanced stage and in those with several other poor prognostic factors. The finding that
cervical adenocarcinomas exhibited greater VEGF expression and microvessel density than squamous cell car-
cinomas may explain the poorer prognosis of adenocarcinoma compared with squamous cell carcinoma. More-
over, microvessel density in squamous cell carcinomas was significantly correlated with poor prognostic factors.
Therefore, there is possibility that bevacizumab, a humanized monoclonal antibody against VEGF-A, may be
useful in the initial treatment targeting angiogenesis for early-stage cervical cancer. J. Med. Invest. 62 : 154-
160, August, 2015
Keywords : cervical cancer, vascular endothelial growth factor, microvessel density, bevacizumab, angiogenesis
Received for publication December 5, 2014 ; accepted February 17, 2015.
Address correspondence and reprint requests to Yasuyo Saijo, MD, De-
partment of Obstetrics and Gynecology, Institute of Health Biosciences,
the University of Tokushima Graduate School, 3 -18 -15 Kuramoto-cho,
Tokushima 770-8503, Japan and Fax : +81-88 -631-2630.
The Journal of Medical Investigation Vol. 62 2015
154
40 on poly-L- lysine-coated slides, deparaffinized, and rehydrated.
The methods used for antigen retrieval are described in Table 1.
After washing with distilled water, the slides were incubated for 10
min in 3% hydrogen peroxide to inactivate endogenous peroxidase
activity. We stained the tissue sections according to the standard
avidin-biotin-peroxidase complex method using a LSAB2 Kit em-
ploying peroxidase (Dako, Glostrup, Denmark). After incubation
for 10 min with 0.25% casein in phosphate-buffered saline (PBS)
containing carrier protein to eliminate nonspecific background
staining, the slides were covered with primary antibody solution
and incubated for 120 min at room temperature. The primary anti-
bodies used are listed in Table 1. After washing with Tris-buffered
saline (TBS) containing 0.1% Tween 20 (TTBS), the slides were
incubated for 30 min with a solution containing biotinylated anti -
mouse and anti -rabbit immmunoglobulin G at room temperature.
They were then incubated in peroxidase-conjugated avidin solution
for 20 min and washed with TTBS. Color was developed using dia-
minobenzidine, and counterstaining was performed with Mayer’s
hematoxylin. The positive control treatments for VEGF (12) are
described in Table 1. Samples treated with normal serum in place
of primary antibodies served as the negative control. VEGF stain-
ing specificity was confirmed by the preabsorption of the primary
antibody with VEGF peptides (Fig. 1).
Semiquantification of immunostaining results
The immunostained sections were semiquantitatively evaluated
by investigators who had no knowledge of the clinical status of the
patient. VEGF expression in tumor cells was evaluated as previously
described (13, 14). After screening each section as a whole, micro-
scopic fields were selected using a random point grid and the mean
percentage of specifically brown immunostained tumor cell areas
in five microscopic fields at 200magnification (1.33 mm2 per field)
was determined. The scores were as follows : 0%=0 ; 1-25%=1 ;
26-50%=2 ; 51-75%=3 ; and 76-100%=4. The mean intensities of
the immunostained areas based on the arbitrary numerical values
were recorded as follows : none=0 ; weak=1 ; moderate=2 ; and
strong=3. We judged that moderate staining was comparable to the
staining intensity observed for positive control sections (Figs. 2
and 3). To obtain semiquantitative values for VEGF antigens per
tissue, the score for the percentage of positively stained cells and
intensity of the staining obtained for each section were multiplied
(range, 0-12) and the overall antigen expression was categorized
as follows : 0, negative ; 1 -4, low ; and 6-12, high.
Microvessel density
According to a previously described method, the sections were
scanned at low magnification (40-100) to identify the most vas-
cularized areas within the tumor samples (15). Within these areas,
microvessels were counted in a 200magnified field. Any area of
brown-stained endothelial cells that was clearly separated from the
adjacent microvessels, tumor cells, and other connective tissue ele-
ments was considered a single countable microvessel. Microves-
sel density was calculated by adding the numbers of microvessels
in 15 fields for each sample.
Statistical analysis
Statistical analysis was performed using Mann-Whitney U tests
and Fisher’s exact probability tests. The correlation between VEGF
expression and microvessel density was examined using the Spear-
man’s rank correlation test. The Kaplan-Meier method and log
rank tests were used to clarify whether VEGF expression and mi-
crovessel density are predictive of prognosis in cases of cervical
cancer.
RESULTS
Correlations between VEGF expression and clinicopathological
parameters
VEGF expression was observed in all 50 samples (Figs. 3A, B).
The average semiquantitative VEGF expression values in cases of
squamous cell carcinoma and adenocarcinoma were 4.41.8 and
Table 1. Immunostaining : Antigen retrieval, Primary antibody, and
Positive control
Antigen retrieval
VEGF 0.4% pepsin in 0.2M HCl solution, 37, 15 min
CD31 proteinase K, room temperature, 8 min (Dako, Glostrup,
Denmark)
Primary antibody
VEGF rabbit anti -human VEGF (C-1),
monoclonal, at 15 μg/mL (Santa Cruz Biotechnology,
Santa Cruz, CA, USA)
CD31 mouse anti -human CD31,
monoclonal (clone JC70A, prediluted : Dako, Glostrup,
Denmark)
Positive control
VEGF normal placenta
Figure 1. Antibody absorption test using VEGF peptides
The specificity of immunostaining was confirmed by testing absorption between the primary antibody and VEGF peptides. (A) Positive staining
for VEGF, (B) staining of VEGF absorbed to VEGF peptides. Magnification, 200in (A), (B).
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7.31.8, respectively, and VEGF expression was significantly
higher in adenocarcinomas than in squamous cell carcinomas (P
0.001 ; Table 2). In addition, elevated VEGF expression was ob-
served in a significantly larger proportion of adenocarcinomas com-
pared with squamous cell carcinomas [88.24% (15 cases) vs. 18.75%
(6 cases), P0.001 ; Table 3]. However, there were no significant
correlations between VEGF expression and the assessed clinico-
pathological parameters (Table 4).
Correlations between microvessel density and clinicopathological
parameters
Microvessel density was evaluated by detecting CD31-positive
cells and counting the corresponding vessels (Figs. 3D, E). Mi-
crovessel density was significantly greater in adenocarcinoma sam-
ples than that in squamous cell carcinoma samples (P=0.013 ;
Table 2). In cases of adenocarcinoma, no significant correlations
were observed between microvessel density and the assessed
clinicopathological parameters. In contrast, microvessel density was
significantly greater in squamous cell carcinoma samples than that
in advanced stage carcinoma samples and in those with deeper
myometrial invasion, vaginal involvement, lymph node metasta-
sis, lymphovascular space invasion, and a high recurrence rate
(Table 5).
Correlations among VEGF expression, microvessel density, and
prognosis
A weak but significant correlation was observed between VEGF
expression and microvessel density (data not shown). Using the
Kaplan-Meier method and log rank tests, no significant correla-
tions were observed between VEGF expression and overall sur-
vival or disease- free survival or between microvessel density and
overall or disease- free survival. These same results were obtained
for both adenocarcinoma and squamous cell carcinoma (data not
shown).
DISCUSSION
Angiogenesis plays a key role in tumor growth and metastasis.
Although angiogenic factor expression and microvessel density
have been reported to be markers of tumor malignancy, their utility
in cervical cancer remains controversial. A significant correlation
was reported between VEGF protein expression and prognostic
factors in cervical cancer lesions (6). However, another study re-
ported no significant correlations between VEGF mRNA expres-
sion levels and prognostic factors in cervical cancer tissues (4).
The correlation between microvessel density and cervical cancer
prognosis is also controversial. Several studies have demonstrated
that high microvessel density is a useful indicator of cervical can-
cer prognosis (16, 17). Randall et al. reported that increased tumor
angiogenesis measured according to CD31-positive microvessel
density is an independent prognostic marker of improved progres-
sion- free and overall survival. They hypothesized that increased
microvessel density is associated with improved treatment response
due to better chemotherapeutic delivery and enhanced radiation
therapy in well -oxygenated tumors (18). Cervical adenocarcinoma
is associated with lower survival compared with squamous cell car-
cinoma (19-21). Another study reported that microvessel density
and VEGF mRNA expression were significantly higher in cervical
adenocarcinoma than in squamous cell carcinoma, although no
Figure 2. Representative examples of VEGF immunostaining
The intensity of immunostaining was semiquantified as none : 0, weak :
1, moderate : 2, and strong : 3. (A) Typical example of weak staining
(squamous cell carcinoma), and (B) typical example of moderate stain-
ing (adenocarcinoma). Magnification, 100.
Table 2. VEGF expression and microvessel density by histological types
VEGF expression score Microvessel density
Squamous cell carcinoma 4.41.8 488.6189.4
(n=32)
Adenocarcinoma 7.31.8 678.5242.5
(n=17)
P0.001* P=0.013*
*Mann-Whitney’s U test (P0.05)
Data are presented as meanstandard deviation.
Table 3. VEGF expression score by histological types
VEGF expression score
Low
(score 1-4)
High
(score 6-12)
Squamous cell carcinoma 26 cases 6 cases
(n=32) (81.25%) (18.75%)
Adenocarcinoma 2 cases 15 cases
(n=17) (11.76%) (88.24%)
P0.001*
*Fisher’s exact probability test (P0.05)
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Table 4. Clinicopathological parameters and VEGF expression score (meanS.D.)
Squamous cell carcinoma Adenocarcinoma
Valiable n VEGF expression score P value* n VEGF expression score P value*
Stage (FIGO)
 19 3.91.4 NS 13 7.61.4 NS
 13 5.12.1 4 6.53.0
Cervical infiltration depth
<2/3 13 4.61.9 NS 9 7.41.8 NS
2/3 19 4.01.7 8 7.32.0
Parametrial involvement
Positive 7 4.92.3 NS 4 8.00 NS
Negative 25 4.21.7 13 7.22.1
Vaginal involvement
Positive 9 4.62.2 NS 6 7.02.4 NS
Negative 23 4.31.7 11 7.51.5
Pelvic lymph node metastasis
Positive 11 4.21.4 NS 4 8.00 NS
Negative 21 4.52.0 13 7.22.1
Lymphovascular permeation
Positive 22 4.21.7 NS 9 7.41.7 NS
Negative 10 4.72.1 8 7.32.1
Recurrence
Yes 7 4.61.5 NS 4 8.00 NS
No 25 4.31.9 13 7.22.1
*Mann-Whitney’s U test (P0.05)
Figure 3. Immunohistochemical staining for VEGF in squamous cell carcinoma (A), in adenocarcinoma (B), in normal placenta as a positive
control (C), and staining for CD31 in squamous cell carcinoma (D) and adenocarcinoma (E). VEGF expression and microvessel density were
significantly greater in adenocarcinomas than in squamous cell carcinomas. Magnification, 100in (A), (B), (D), (E) and 400in (C).
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prognostic significance could be demonstrated for microvessel den-
sity or VEGF expression (22). In the present study, we observed a
significant correlation between VEGF expression and microvessel
density and both were significantly higher in adenocarcinoma
samples than in squamous cell carcinoma samples. These findings
may explain the aggressive behavior of adenocarcinomas. More-
over, in cases of squamous cell carcinoma, microvessel density was
significantly greater in the presence of poor prognostic factors, in-
cluding advanced stage carcinoma, deeper myometrial invasion,
vaginal involvement, lymph node metastasis, lymphovascular space
invasion, and a high recurrence rate. However, no significant cor-
relations were observed between these factors in cases of adeno-
carcinoma. One explanation for this discrepancy is that the number
of adenocarcinoma samples (n=17) was too small to yield signifi-
cant results. Another possibility is that most cases of adenocarci-
noma demonstrated high VEGF expression levels and high mi-
crovessel density, making it difficult to detect differences with
statistical significance.
Currently, the optimal treatment strategy for stage Ib-IIb early
cervical cancer remains unknown. Many countries accept concur-
rent radiotherapy (CCRT) as a standard initial treatment, and it is
sometimes used postoperatively as well (23-26). Radiotherapy
(RT) is becoming somewhat indispensable but for maximizing the
long-term quality of life of a patient with cervical cancer, the typi-
cal late side effects of RT, such as lower extremity edema and
gastrointestinal obstruction, must be considered and minimized.
Cervical cancer treatment requires adjustments according to the
circumstances of each case, and such adjustments can include
avoiding RT as an initial treatment, performing surgery after a pre-
operative course of neoadjuvant chemotherapy, selecting chemo-
therapy (CT) for postoperative treatment, and resorting to RT in
cases of subsequent recurrence of localized cancer within the pelvis.
Using these treatment approaches, a favorable progression-free
survival rate was reported for the treatment of patients with stage
Ib2-IIb cervical cancer (27).
For cervical adenocarcinoma, there is no solid evidence regarding
the most effective treatment approach (28). Many studies report
that the use of RT within the pelvis is more effective for suppress-
ing squamous cell carcinoma than adenocarcinoma (29-32). A
recent study reported no appreciable difference in the 5-year
survival rate when RT, including CCRT, was compared with CT
alone in the postoperative treatment of stages Ib-IIb cervical ade-
nocarcinoma (33). Thus, avoiding RT and applying surgery and
CT in treating early cervical adenocarcinoma should be thoroughly
considered.
Bevacizumab (Avastin), a humanized monoclonal antibody di-
rected against VEGF-A, has been reported to be effective in cases
of recurrent squamous cell carcinoma of uterine cervix (34). In the
present study, squamous cell carcinoma tissues clearly exhibited
high microvessel density, suggesting the potential applicability of
bevacizumab. In addition, VEGF expression in adenocarcinoma was
significantly greater than that in squamous cell carcinoma along
with a high microvessel density, which further indicates the poten-
tial effectiveness of bevacizumab for treating adenocarcinoma. In
Table 5. Clinicopathological parameters and microvessel density (meanS.D.)
Squamous cell carcinoma Adenocarcinoma
Valiable n Microvessel density P value* n Microvessel density P value*
Stage (FIGO)
 19 441.3198.4 0.043 13 705.4249.0 NS
 13 557.8158.0 4 591.0228.6
Cervical infiltration depth
<2/3 13 376.4165.5 0.004 9 629.0264.5 NS
2/3 19 565.4168.0 8 734.1218.5
Parametrial involvement
Positive 7 588.7183.4 NS 4 646.5173.0 NS
Negative 25 460.6185.0 13 688.3265.4
Vaginal involvement
Positive 9 598.0132.2 0.023 6 582.5177.7 NS
Negative 23 445.8193.4 11 730.8264.1
Pelvic lymph node metastasis
Positive 11 624.0161.1 0.005 4 743.8290.9 NS
Negative 21 417.7165.2 13 658.4253.3
Lymphovascular permeation
Positive 22 542.1187.8 0.015 9 693.2236.3 NS
Negative 10 371.0137.3 8 661.9264.5
Recurrence
Yes 7 650.7189.0 0.027 4 774.8269.5 NS
No 25 443.2166.2 13 648.8237.1
*Mann-Whitney’s U test (P0.05)
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August 2014, the FDA approved bevacizumab for cervical cancer
treatment in cases of recurrence or progression (11). Because in-
creased VEGF expression was observed in this study in cases of
early invasive cancer (stage I and II), targeting angiogenesis as an
initial strategy in cervical cancer treatment appears promising and
raises new expectations for improvements in long-term survival
among patients with a condition for which such expectations have
not existed for many years.
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